Drug Overview

Tisotumab vedotin-tftv is an antibody, drug conjugate (ADC) targeted therapy used in advanced gynecologic oncology, designed to deliver a potent chemotherapy payload directly to tumor cells that express tissue factor, thereby limiting damage to normal tissues. As a “Smart Drug” and targeted therapy, it integrates precise monoclonal antibody targeting with a cytotoxic microtubule inhibitor to enhance antitumor activity.

Generic name
- Tisotumab vedotin-tftv.
US Brand names
- Tivdak.
Drug Class
- Antibody–drug conjugate (ADC).
- Tissue factor (TF)–directed targeted therapy.
- Contains monomethyl auristatin E (MMAE), a microtubule-disrupting antineoplastic agent, as the cytotoxic payload.
Route of Administration
- Intravenous (IV) infusion only.
FDA Approval Status
- Initially granted accelerated approval in the United States for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
- Converted to traditional (full) approval in 2024 based on confirmatory trial data in this population.
- Indicated after progression following at least one prior systemic regimen for recurrent or metastatic disease.

What Is It and How Does It Work? (Mechanism of Action)

Tisotumab vedotin-tftv is a targeted antibody-drug conjugate (ADC) that binds tissue factor on tumors, internalizes, and releases MMAE to disrupt microtubules and kill cancer cells.

Binds tissue factor (TF), overexpressed on cervical tumors but is limited on normal tissues
Internalizes via receptor-mediated endocytosis to lysosomes
Proteases cleave the linker, releasing MMAE into the cytoplasm
MMAE binds tubulin, inhibits polymerization, causes G2/M arrest and apoptosis
Bystander effect kills nearby TF-low cells
May disrupt TF-FVIIa signaling, reducing angiogenesis/proliferation

FDA-Approved Clinical Indications

Tisotumab vedotin-tftv targets advanced cervical cancer post-chemotherapy, with no non-oncologic uses.

Recurrent or metastatic cervical cancer after prior systemic therapy (e.g., platinum-based)
Oncological uses (if any): TF-directed ADC for pretreated cervical cancer
Non-oncological uses (if any): None

Dosage and Administration Protocols

IV infusion every 3 weeks with premeds and eye prophylaxis; adjust for toxicity, caution in hepatic impairment.

*Indication*	*Standard Dose*	*Frequency*	*Infusion Time*	*Key Administration Notes*	*Dose Adjustments (Renal/Hepatic & Toxicity)*
Recurrent or metastatic cervical cancer (adult)	2.0 mg/kg (up to a maximum dose per infusion, typically capped in labeling)	Every 3 weeks (21-day cycle)	Initial infusion over 30 minutes; subsequent infusions may remain at 30 minutes as tolerated	IV infusion through a dedicated line; requires premedications (e.g., corticosteroid, antihistamine, antipyretic) to reduce infusion reactions, plus prophylactic eye drops, cold eye masks, and ophthalmic evaluations to prevent ocular toxicity	No starting dose adjustment for mild to moderate renal impairment; limited data in severe renal impairment, use caution or avoid. For hepatic impairment, generally avoid in moderate to severe cases (elevated bilirubin); assess baseline AST/ALT and bilirubin levels. Hold, reduce, or discontinue for Grade 2–4 ocular events, severe peripheral neuropathy, hemorrhage, or other serious adverse events according to severity grading.

(Specific numerical caps and detailed dose-reduction steps should follow current prescribing information in clinical practice.)

Clinical Efficacy and Research Results

Between 2020 and 2025, clinical programs such as innovaTV 204 and innovaTV 301 have shown tisotumab vedotin-tftv to provide meaningful responses and survival benefits in heavily pretreated cervical cancer, where options are limited.

In the phase II innovaTV 204 trial of recurrent/metastatic cervical cancer after prior chemotherapy, tisotumab vedotin produced an objective response rate (ORR) of approximately 24%, with a median duration of response around 8.3 months, a median progression-free survival (PFS) of about 4.2 months, and a median overall survival (OS) of roughly 12 months.
Responses included complete and partial responses in patients who had progressed on prior platinum-based therapy, reflecting activity in a resistant population.

Safety Profile and Side Effects

Tisotumab vedotin-tftv does not carry a traditional boxed warning but has prominent warnings and precautions, especially for ocular toxicity, bleeding, and peripheral neuropathy, requiring structured prophylaxis and monitoring.

Common side effects (>10%)

These adverse events are frequent but often manageable with proactive supportive care and dose modifications.

Ocular events (conjunctivitis, dry eye, keratitis, blurred vision) occur in a substantial proportion of patients (often >40% cumulatively across types).
Epistaxis and other low-grade bleeding events due to tissue factor targeting (nosebleeds, mild mucosal bleeding).
Alopecia, fatigue, nausea, diarrhea, decreased appetite, and abdominal pain are each commonly reported in >10–20% of patients.
Peripheral neuropathy (sensory) and paresthesia occur in a significant minority, increasing with cumulative exposure.
Management strategies for common events
- Use prophylactic ophthalmic drops (steroid and lubricating), cold eye masks during infusion, and regular ophthalmologic exams; adjust or hold treatment if eye symptoms worsen.
- Administer antiemetics for nausea, antidiarrheal medications for diarrhea, and nutritional support for decreased appetite.
- Monitor for neuropathic symptoms at each visit; reduce dose or hold therapy for persistent Grade 2 neuropathy and discontinue for Grade 3–4 neuropathy.

Serious adverse events

Serious toxicities are less common but may require dose interruption or permanent discontinuation.

Severe ocular events (e.g., corneal ulceration, severe keratitis, vision loss if untreated).
Major hemorrhagic events (e.g., hematuria, gastrointestinal or vaginal bleeding).
Grade 3–4 peripheral neuropathy with functional impairment, sometimes irreversible if therapy continues.
Infusion-related reactions (hypersensitivity, fever, chills, respiratory symptoms).

Management strategies for serious events

Serious events require urgent assessment and prompt treatment changes.

Interrupt therapy immediately for significant ocular symptoms and obtain urgent ophthalmology review; restart only if toxicity improves sufficiently.
Investigate clinically relevant bleeding with labs and imaging; hold or discontinue treatment according to severity and need for transfusion or intervention.
Discontinue for Grade 3–4 neuropathy or recurrent severe infusion reactions and initiate appropriate neurologic or allergy-directed management.

Connection to Stem Cell and Regenerative Medicine (Research Areas)

Current evidence places tisotumab vedotin-tftv primarily within targeted ADC strategies for solid tumors rather than stem cell or regenerative medicine.

Research is exploring combinations with immune checkpoint inhibitors and their use in earlier cervical cancer lines.
Tissue factor–targeting ADCs are also being studied in other tumors such as ovarian and head and neck cancers, expanding oncologic applications rather than regenerative uses.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

Baseline evaluation focuses on ocular health, organ function, and neurologic status.

Comprehensive eye exam (visual acuity, slit-lamp, ocular surface assessment).
Full blood count, liver and renal function tests, and coagulation profile.
Blood pressure measurement, performance status, and evaluation of any pre-existing neuropathy.

Precautions during treatment

Ongoing precautions help minimize toxicity and detect complications early.

Use prescribed ocular prophylaxis (steroid and lubricating drops, cold eye packs) and other protective measures as directed.
Arrange regular eye exams, especially before cycles or if new ocular symptoms occur.
Monitor at each visit for bleeding, neurologic changes, and infusion-related symptoms.

Do’s and Don’ts

Clear behavioral guidance supports safer treatment and timely reporting of problems.

Do report eye pain, redness, blurred vision, or excessive tearing without delay.
Do use eye drops exactly as prescribed and attend all scheduled eye and infusion appointments.
Do notify the team about new or worsening numbness, tingling, weakness, or unusual bleeding or bruising.
Don’t wear contact lenses unless specifically approved by an eye specialist.
Don’t skip infusions or lab monitoring, as they are critical for safety and efficacy.
Don’t attempt to self-manage severe symptoms; seek urgent care for sudden vision changes, heavy bleeding, chest pain, or severe shortness of breath.

Legal Disclaimer

The information provided here is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Patients and caregivers should always consult qualified healthcare professionals for individualized recommendations, and clinicians should refer to the most current approved prescribing information and clinical guidelines before initiating or modifying therapy with tisotumab vedotin-tftv.